Researchers are developing an innovative biomaterial-based vaccine aimed at preventing infections associated with implanted orthopedic devices, a major complication despite sterile techniques and antibiotics. In a preclinical study, mice vaccinated with a slowly degradable injectable scaffold vaccine five weeks before implantation showed about a 100-fold reduction in bacterial burden on orthopedic implants compared with traditional soluble vaccines. The vaccine works by creating a localized immune “training ground” that recruits key immune cells and sustains exposure to Staphylococcus aureus antigens—the bacteria most commonly responsible for prosthetic device infections—potentially improving cell-mediated immunity and offering cross-protection even against resistant strains. If successfully translated to humans, this approach could become a preoperative preventive strategy to significantly lower infection rates in joint replacement and other implant surgeries.